Navigation Links
Medivation Presents Positive New Data on Dimebon's Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimer's Disease
Date:7/30/2008

tudy Group. The study met its primary endpoint of safety and tolerability; in addition, Dimebon showed statistically significant benefit versus placebo in cognition as measured by the Mini-Mental State Examination, a secondary endpoint in the study. Huntington's disease is a progressive neurodegenerative disease characterized by the gradual development of involuntary muscle movement, progressive deterioration of cognitive processes and memory and severe behavioral disturbances. There are currently no approved drugs in the United States to treat this uniformly fatal genetic disorder.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding future clinical development plans, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of t
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
2. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
3. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
4. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
5. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
6. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
7. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
8. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
9. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
10. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
11. Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimers Disease 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... PAUL, Minn. , July 30, 2015 ... medical devices using neuroblocking technology to treat obesity, metabolic ... will host a conference call on Thursday, August 6, ... results for the second quarter ended June 30, 2015, ... the Company,s vBloc® Neurometabolic Therapy, delivered via the Maestro® ...
(Date:7/30/2015)... July 30, 2015 ... reports analyzing tumor biomarker tests, imaging, endoscopy ... for the global industry by technology and ... Industry (Tumor Biomarker Tests, Imaging, Endoscopy and ... talking about 9 companies and supported with ...
(Date:7/29/2015)... Ill. , July 30, 2015  Astellas ... ACTIVE study evaluating the efficacy and safety of ... CRESEMBA® (isavuconazonium sulfate), under development for adults with ... Results from the study demonstrated that the trial ... in overall treatment response in isavuconazole-treated patients at ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 3Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 2Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 3Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 4Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 5Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 6Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5
... Inc. Magazine has ranked Precision Therapeutics ... growing privately owned companies in the U.S. with a ... This award recognizes the significant accomplishments of the fastest-growing ... established them among the best in their industries.  Precision ...
... 2011 /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain Drugstore Ltd. ... drugstore chain in China based on the number of ... directors has authorized a share repurchase program. Under the ... up to US$20 million worth of its issued and ...
Cached Medicine Technology:Precision Therapeutics Named on Inc. 500|5000 2011 List and Recognized for Achievements in Personalized Medicine Industry 2Precision Therapeutics Named on Inc. 500|5000 2011 List and Recognized for Achievements in Personalized Medicine Industry 3China Nepstar Chain Drugstore Announces Share Repurchase Program 2China Nepstar Chain Drugstore Announces Share Repurchase Program 3
(Date:7/30/2015)... ... July 30, 2015 , ... ... ‘Mary Jo Lawyer-Spano Mesothelioma Patient Registry Act of 2015’. The bill was ... Collins (R-NY), Peter King (R-NY), Betty McCollum (D-MN), Joe Kennedy (D-MA), and Leonard ...
(Date:7/30/2015)... ... , ... Western University of Health Sciences faculty, students and alumni were a ... sports and humanitarian event in the world this year and the single biggest event ... 25 through August 2, 2015, benefited from the participation of WesternU’s colleges of osteopathic ...
(Date:7/30/2015)... ... ... Between 2012 and 2014 HIV infection rates rose from five to seven percent ... untreated heroin use disorders share their needles and spread the infection. Florida does not ... Ultimately Florida’s HIV infection rates have bolstered to 23 percent due to lack of ...
(Date:7/30/2015)... ... 2015 , ... Gummy smile surgeon, Dr. Alex Farnoosh, now offers ... well as the patented gum depigmentation treatmet. Dr. Farnoosh is a renowned dentist with ... from around the world. , “Like treatment of any other disease or condition, making ...
(Date:7/30/2015)... NY (PRWEB) , ... July 30, 2015 , ... ... at Mount Sinai Earns National Cancer Institute Designation , The Tisch Cancer Institute ... a National Cancer Institute (NCI)-designated cancer center. TCI joins an elite group of ...
Breaking Medicine News(10 mins):Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6
... A class of drugs known as the triptans are known ... Since there are seven different triptan drugs available, it is ... at the University of Netherlands have carried out an ... over 18,000 patients. They find that in comparison with the ...
... to a new study, it shows that warfarin and aspirin ... patients at risk. Aspirin prevents blood clotting by stopping platelets ... blood clotting proteins. So both are known to help prevent ... date, it has been thought that warfarin is more effective ...
... the smallpox vaccine is being tested against cervical cancer. ... cervical cancer cases, but not everyone with the virus ... worldwide each year and causes 300,000 deaths. If it ... is a high survival rate. // ,Doctors ...
... sperm is the best indicator of a man's fertility, ... According to Dr. Dav Guzhik, chairman of obstetrics and ... infertility depends upon first establishing what's normal and abnormal. ... semen as normal if it contains 10 million sperm ...
... irregular or very long menstrual cycles have a higher ... needn't panic because the risk can be reduced markedly ... control. // ,Menstrual cycles 40 days or ... some sort of underlying metabolic abnormality. "Over an eight-year ...
... started menstruation could affect whether you suffer allergies.This is due ... development of the child. ,The study of Finnish ... ago. More than 4,740 pregnant women had been asked about ... their children in thirties were given allergy tests against types ...
Cached Medicine News:
The care package includes a spare motor, fuse, Spare Fluorescent Bulb, additional Vibratome Feather Blades, Specimen Adhesive, Specimen Mounting Blocks, and a Specimen Tray....
... several (10 to 12) brain slices to ... while maintaining excellent viability. A mixture of ... saline. This initiates a circular flow and ... slices. Slices remain viable for hours while ...
... cooling water for the Vibratome 900R when it is ... in a location which has no source of tap ... thermoelectric heat pump. The reservoir tank holds seven ... 900R for up to eight hours. Water is ...
Punch set for Advanced Tissue Arrayer, 0.6 mm...
Medicine Products: